Showing results (31-40 of 292) with videos related to
Sort By:
Pageof 30
Journal of Market Access & Health Policy|February 1, 2020
Tendering and biosimilars: what role for value-added services?Steven Simoens, Raymond CheungHealth Policy (Amsterdam, Netherlands)|May 3, 2005
Voluntary or compulsory health care reform? The case of primary care organisations in ScotlandSteven Simoens, Anthony ScottExpert Review of Pharmacoeconomics & Outcomes Research|January 26, 2024
Drug pricing and transparency in Europe and the United States: what is it and how does it work?Steven Simoens, Mondher ToumiFrontiers in Medicine|November 12, 2021
R&D Costs of New Medicines: A Landscape AnalysisSteven Simoens, Isabelle HuysPharmaceuticals (Basel, Switzerland)|May 28, 2022
Emerging Insights into European Markets of Biologics, Including BiosimilarsSteven Simoens, Isabelle HuysPharmacoeconomics|July 30, 2011
Does the market share of generic medicines influence the price level?: a European analysisPieter Dylst, Steven SimoensDrug Discovery Today|December 5, 2021
How much do the public sector and the private sector contribute to biopharmaceutical R&D?Steven Simoens, Isabelle HuysPharmaceuticals (Basel, Switzerland)|October 8, 2016
Generic Medicine Pricing Policies in Europe: Current Status and ImpactPieter Dylst, Steven SimoensJournal of Health Organization and Management|June 13, 2003
How are Scottish integrated primary care organisations managed?Steven Simoens, Anthony ScottHealth Services Management Research|April 6, 2005
Integrated primary care organizations: to what extent is integration occurring and why?Steven Simoens, Anthony ScottPageof 30